Once again the S&P / ASX 200 (Index: ^AXJO) (ASX: XJO) is travelling sideways as investors hold fire before February’s interim reporting season and the possibility of an interest rate cut delivered by the RBA next week.
However, there are several stocks soaring ahead already and with potentially positive interim or full year results coming up, it’s worth taking a closer look at them.
Premier Investments Limited (ASX: PMV) is the owner and operator of one of the world’s hottest stationery brands in Smiggle, which is a provider of accessories and school essentials for children. The Smiggle brand is now expanding successfully into the UK and has been the outstanding performer amongst Premier Investments’ stable of retail brands. The stock has climbed 23 cents or 2.23% to $10.52 today.
Premier’s chairman and largest shareholder is retail entrepreneur Solomon Lew, who also holds a substantial interest in successful kitchen appliance business Breville Group Ltd (ASX: BRG).
AMP Limited (ASX: AMP) is an asset management and insurance business that has climbed 13 cents or 2.28% today as investors look forward to a potentially positive full year result in February.
The group is expected to post improved net fund inflows and show further signs that it is turning around its previously ailing Wealth Protection life insurance business. If these two groups deliver positive numbers in February the stock (including a decent yield) may receive further support.
Capitol Health Ltd (ASX: CAJ) is a diagnostic imaging healthcare business based in Victoria that has seen its shares climb 5.5 cents or 6.88% today to 85.5 cents. The stock has nearly doubled in value over the past year after acquisitive and organic growth saw financial year 2014’s net profit of $7.2 million double 2013’s effort. The result was on $90 million of revenues and given Capitol Health is still a young business the prodigious growth rates may be here to stay for a while yet.
Phytotech Medical Ltd (ASX: PYL) is a recently listed medical marijuana business that continues to light up the ASX having gained 4 cents or 7.77% today. Investors are clearly expecting the business to be a success on the basis of growing demand for medical marijuana in a fast-growing international market.
Having raised $5.9 million at 20 cents per share at the IPO stage, the on-market price of 55.5 cents is looking a bit fruity and given the risks investors might want to consider giving this one a miss.